ARTICLE | Clinical News
SD-101: Preliminary Ph Ib MEL-01 data
November 11, 2016 8:54 PM UTC
Preliminary data from 5 evaluable patients with unresectable stage IIIc or IV melanoma who were naïve to anti-PD-1 treatment in the dose-escalation Phase Ib portion of the open-label, U.S. Phase Ib/II...
BCIQ Company Profiles
BCIQ Target Profiles